Marker Therapeutics, Inc. Share Price & Technical Analysis
MRKR · $1.40 (-2.10%)
Healthcare / Biotechnology
$1.40
-2.10%
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associ…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
0% return in May, 36% avg return in past 3 year May month.
9% return in 2026, 49% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | -6% | -7% | 15% | 0% | – | – | – | – | – | – | – | 9% |
| 25 | -45% | -17% | -20% | 0% | 33% | -6% | -7% | -36% | 0% | 11% | 20% | 15% | -51% |
| 24 | -15% | -23% | 19% | -9% | -5% | 38% | -9% | -25% | -20% | 46% | -15% | -9% | -25% |
| 23 | 12% | -21% | -68% | 14% | 80% | 82% | 65% | 6% | -20% | -47% | 17% | 104% | 223% |
| 22 | -33% | -40% | 19% | -26% | -14% | 10% | -6% | -3% | 16% | 16% | -30% | -10% | -102% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$24.26M
P/E ratio
—
52W high
$4.07
52W low
$0.81
Volume
63,234
Beta
1.43
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Marker Therapeutics, Inc. share price today?
- Marker Therapeutics, Inc. (MRKR) last traded around $1.40 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MRKR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MRKR. Download the app for real-time alerts.
- How can I analyze Marker Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.